Natriuretic Peptides (ANP, BNP) in Heart Health
Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
Natriuretic peptides, such as ANP and BNP, are crucial biomarkers and regulators of cardiovascular health, particularly in the context of heart failure.
The Role of Natriuretic Peptides in Cardiovascular Homeostasis
Natriuretic peptides are a family of hormones that play a critical role in maintaining cardiovascular homeostasis. The two main natriuretic peptides are atrial natriuretic peptide (ANP), which is primarily produced by the atria of the heart, and brain natriuretic peptide (BNP), which is primarily produced by the ventricles of the heart. These peptides are released in response to increased cardiac wall stress and volume overload, and they act to promote natriuresis (sodium excretion), diuresis (water excretion), and vasodilation, thereby reducing blood pressure and cardiac workload.
Mechanism of Action
Natriuretic peptides exert their effects by binding to natriuretic peptide receptors (NPRs), which are located on various cells, including kidney cells, vascular smooth muscle cells, and endothelial cells. There are three main types of NPRs: NPR-A (also known as guanylyl cyclase-A or GC-A), NPR-B (guanylyl cyclase-B or GC-B), and NPR-C (clearance receptor). ANP and BNP primarily bind to NPR-A, while C-type natriuretic peptide (CNP), another member of the family, preferentially binds to NPR-B [1].
The binding of natriuretic peptides to NPR-A and NPR-B activates their intrinsic guanylyl cyclase activity, leading to an increase in intracellular cyclic guanosine monophosphate (cGMP). cGMP then acts as a second messenger, mediating the various physiological effects of natriuretic peptides. These effects include:
Vascular smooth muscle relaxation: cGMP activates protein kinase G (PKG), which phosphorylates various proteins involved in smooth muscle contraction, leading to vasodilation and reduced systemic vascular resistance [2].
Renal effects: In the kidneys, cGMP promotes afferent arteriolar vasodilation and efferent arteriolar constriction, increasing glomerular filtration rate (GFR). It also inhibits sodium reabsorption in the renal tubules and suppresses renin and aldosterone secretion, leading to natriuresis and diuresis [3].
Cardiac remodeling inhibition: Natriuretic peptides have been shown to attenuate cardiac hypertrophy and fibrosis, which are hallmarks of heart failure progression [4].
Sympathetic nervous system modulation: They can suppress sympathetic nervous system activity, further contributing to blood pressure reduction and reduced cardiac workload [5].
NPR-C, in contrast, lacks guanylyl cyclase activity and is primarily involved in the metabolic clearance of natriuretic peptides, acting as a "decoy" receptor [6].
Natriuretic Peptides as Biomarkers for Heart Failure
BNP and its N-terminal pro-hormone, NT-proBNP, are well-established biomarkers for the diagnosis and prognosis of heart failure (HF). In heart failure, the ventricles are unable to pump blood effectively, leading to an increase in cardiac wall stress and the release of BNP and NT-proBNP into the bloodstream. Measuring the levels of these peptides can help to confirm a diagnosis of heart failure, assess its severity, and predict the risk of future cardiovascular events.
Clinical Utility of BNP and NT-proBNP:
Diagnosis of Acute Decompensated Heart Failure (ADHF): Elevated levels of BNP (>100 pg/mL) or NT-proBNP (>300 pg/mL) are highly suggestive of ADHF in patients presenting with dyspnea [7]. Lower levels can effectively rule out ADHF.
Prognosis in Chronic Heart Failure: Persistently elevated BNP or NT-proBNP levels in patients with chronic HF are associated with an increased risk of hospitalization and mortality [8].
Guidance of Therapy: Some guidelines suggest using natriuretic peptide levels to guide HF therapy, aiming for a reduction in levels to optimize treatment [9].
Risk Stratification: These biomarkers are useful for stratifying risk in asymptomatic individuals with cardiac dysfunction and in patients with acute coronary syndromes [10].
It's important to note that various factors can influence BNP and NT-proBNP levels, including age, renal function, obesity, and atrial fibrillation. Therefore, interpretation should always be done in the context of the patient's overall clinical picture.
Therapeutic Applications of Natriuretic Peptides
The physiological effects of natriuretic peptides have made them attractive therapeutic agents for the treatment of heart failure.
Nesiritide: Recombinant BNP
Nesiritide, a recombinant form of human BNP, has been approved by the FDA for the treatment of acute decompensated heart failure. It is administered intravenously and acts to reduce cardiac preload and afterload, thereby improving symptoms of dyspnea (shortness of breath). Clinical trials have shown that nesiritide can improve hemodynamics and reduce pulmonary capillary wedge pressure in patients with ADHF [11]. However, its use has been associated with a risk of hypotension, and its impact on mortality remains controversial [12].
Neprilysin Inhibitors
Neprilysin (neutral endopeptidase) is an enzyme that degrades natriuretic peptides, as well as other vasoactive peptides like bradykinin. Inhibition of neprilysin leads to increased endogenous levels of natriuretic peptides, enhancing their beneficial cardiovascular effects. Sacubitril/valsartan (Entresto), a combination of a neprilysin inhibitor (sacubitril) and an angiotensin receptor blocker (valsartan), has revolutionized the treatment of heart failure with reduced ejection fraction (HFrEF).
The PARADIGM-HF trial demonstrated that sacubitril/valsartan significantly reduced the risk of cardiovascular death and hospitalization for heart failure compared to enalapril in patients with HFrEF [13]. This dual mechanism of action, enhancing natriuretic peptide effects while blocking the renin-angiotensin-aldosterone system, provides a powerful therapeutic strategy.
Emerging Therapies: Ularitide
Ularitide, a synthetic form of urodilatin (a kidney-derived natriuretic peptide), is another promising agent. It has similar effects to ANP, promoting natriuresis, diuresis, and vasodilation. Studies have investigated its use in ADHF, showing improvements in hemodynamics and renal function [14].
Protocols and Dosing Considerations
Nesiritide for ADHF
Initial Bolus: 2 mcg/kg intravenously over 60 seconds.
Continuous Infusion: 0.01 mcg/kg/min.
Titration: May be increased by 0.005 mcg/kg/min every 3 hours up to a maximum of 0.03 mcg/kg/min, or until desired hemodynamic effect or hypotension occurs.
Monitoring: Close monitoring of blood pressure, heart rate, and urine output is essential.
Sacubitril/Valsartan for HFrEF
Initial Dose: Typically 49/51 mg (sacubitril/valsartan) orally twice daily.
Titration: Double the dose every 2-4 weeks to a target dose of 97/103 mg twice daily, as tolerated.
Considerations: Patients should be stable on an ACE inhibitor or ARB before initiating sacubitril/valsartan. A washout period of at least 36 hours is required when switching from an ACE inhibitor to sacubitril/valsartan to avoid angioedema [15].
Safety Considerations and Contraindications
Nesiritide
Hypotension: The most common adverse effect. Contraindicated in cardiogenic shock or symptomatic hypotension.
Renal Dysfunction: Use with caution in patients with renal impairment.
Contraindications: Cardiogenic shock, symptomatic hypotension, hypersensitivity to nesiritide.
Sacubitril/Valsartan
Angioedema: Increased risk, especially in patients with a history of angioedema with ACE inhibitors. Contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy.
Hypotension: Common, especially during initiation.
Hyperkalemia: Can occur due to the ARB component.
Renal Impairment: Requires dose adjustment in severe renal impairment.
Pregnancy: Contraindicated due to fetal toxicity (ARB component).
Future Directions and Research
Research into the natriuretic peptide system continues to evolve. Novel approaches include:
Targeting NPR-C: Strategies to inhibit NPR-C could reduce natriuretic peptide clearance, thereby increasing their bioavailability and therapeutic effects [16].
Gene Therapy: Investigating gene therapy approaches to enhance endogenous natriuretic peptide production.
Biomarker Refinements: Further research into the utility of other natriuretic peptides (e.g., CNP) and their fragments as biomarkers for specific cardiovascular conditions.
Personalized Medicine: Tailoring natriuretic peptide-based therapies based on individual patient characteristics and biomarker responses.
| Peptide | Primary Source | Primary Stimulus for Release | Clinical Utility | Therapeutic Use |
|---|---|---|---|---|
| ANP | Atria | Atrial stretch, volume overload | Less commonly used as a direct biomarker due to short half-life | Precursor for Ularitide (synthetic urodilatin) |
| BNP | Ventricles | Ventricular stretch, pressure overload | Diagnosis & prognosis of heart failure | Nesiritide (recombinant BNP) for ADHF |
| NT-proBNP | Ventricles (pro-hormone of BNP) | Ventricular stretch, pressure overload | Diagnosis & prognosis of heart failure (longer half-life than BNP) | Indirectly targeted by Neprilysin inhibitors |
Key Takeaways
Natriuretic peptides are hormones that regulate cardiovascular homeostasis.
ANP and BNP are the two main natriuretic peptides, with CNP also playing a role.
They promote natriuresis, diuresis, and vasodilation through cGMP-mediated pathways.
BNP and NT-proBNP are important biomarkers for the diagnosis, prognosis, and management of heart failure.
Natriuretic peptides have significant therapeutic applications in the treatment of heart failure, including recombinant forms (nesiritide) and indirect modulation via neprilysin inhibitors (sacubitril/valsartan).
The natriuretic peptide system is a key player in cardiovascular health, and monitoring natriuretic peptide levels can provide valuable information about heart function.
Therapeutic interventions targeting this system require careful consideration of dosing, monitoring, and potential adverse effects.
---
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy, making changes to your health regimen, or interpreting medical test results. The information provided herein is not intended to diagnose, treat, cure, or prevent any disease.
---
References:
[1] Potter, L. R. (2011). Natriuretic peptide receptors: biochemistry and signal transduction. Current Opinion in Nephrology and Hypertension, 20(1), 32-38.
[2] Kuhn, M. (2012). Molecular physiology of natriuretic peptide signalling. Basic Research in Cardiology, 107(6), 1-13.
[3] Volpe, M. (2014). The natriuretic peptides system: an overview of its role in physiology and cardiovascular disease. Journal of Endocrinological Investigation, 37(12), 1147-1157.
[4] Rubattu, S., et al. (2019
---